Artificial Intelligence
Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business Update
![](https://roboticulized.com/wp-content/uploads/2020/08/predictive-oncology-reports-second-quarter-2020-financial-results-provides-business-update.jpg)
Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine
NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2020 and provided a business update.
Financial and Business Highlights of Q2 and Recent Developments
“During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” commented Dr. Carl Schwartz, Predictive Oncology CEO. “This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare outcomes for cancer patients. Our unique media significantly expands the number of ovarian cancer cell types that can be studied representing nearly 95% of all ovarian cancers, many of which have never been cultured before now, and reduces waste in cancer research.”
“Our acquisitions of Soluble Therapeutics and BioDtech position us with next level capabilities that we believe will materially advance our progress towards developing new targeted therapies in collaborations with pharmaceutical companies and enable meaningful expansion of revenue opportunities,” added Dr. Schwartz. “Soluble Therapeutics assets will help us to provide the best formulation with the highest concentration and the most stable solution for protein and peptide-based drugs while the acquisition of BioDtech gives us governance over its testing solution for unmasking endotoxins. Together, we believe these acquisitions will substantially advance the discipline of precision medicine and accelerate our pursuit of monetizing our full portfolio of assets.”
Dr. Schwartz continued, “We also completed our acquisition of QM in early 2020, bringing its proven, machine learning platform, CoRE, into our portfolio of assets in our Helomics business and equipping us with a framework for an end-to-end solution for precision medicine. We are encouraged by the emerging opportunities this opens for us to further revolutionize AI-driven predictive modeling that can be used to accelerate the development of personalized patient treatments.” “Our Helomics business continues to make solid progress with our CancerQuest 2020 initiative and our collaboration with UPMC Magee Hospital to build AI-driven predictive models for the treatment of ovarian cancer,” added Dr. Schwartz. “Thus far, we have received outcome data, completed the second phase of sequencing and have begun the process to build our AI-model. We are on track to complete the study and have our first AI-driven model in accordance with our workplans, despite a later start date that was triggered by a delay in funding resulting from the COVID-19 pandemic. We expect to have our first AI-driven model completed in the second half of 2020. Just as important, we have been ramping up our commercial outreach activities with large pharma companies to build a pipeline of targeted opportunities ahead of model completion.”
Dr. Schwartz concluded, “We further bolstered our liquidity position with approximately $4.6 million in gross proceeds from a registered direct offering of common stock, the exercise of warrants and the issuance of additional warrants. Although we still have significant short-term debt obligations, the equity offerings demonstrate investor confidence, extend our cash runway and provide working capital to continue our pursuit of developing commercially viable solutions for large pharma. From a governance perspective, we refreshed our board operations with the appointment of three new independent directors, who collectively have extensive industry, financial and business development experience and a rich network of industry contacts that we believe will be extremely advantageous as we execute the next steps in our business plan.”
Second Quarter 2020 Financial Results
Revenues were $183,000 compared with $286,000 for the second quarter of 2019. Revenues in both years were primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY units, of which 1 unit and 7 units were sold in the three months ended June 30, 2020 and 2019, respectively.
Gross margin was 53% in the second quarter of 2020 compared with 59% in the 2019 period. The decrease was due to higher costs on lower revenue in the current period compared to the prior year period. General & administrative expenses decreased 3% to $3.2 million in the second quarter of 2020 as a result of lower costs related to share-based compensation. Operations expenses decreased to $521,000, compared with $1.3 million in the second quarter of 2019. Net loss was $3.6 million, inclusive of other income of $1.3 million related to the revaluation of equity method investments and gains on elimination of notes outstanding, and interest and dividend income, compared with net income of $1.5 million for the second quarter of 2019. The second quarter of 2020 includes a gain on the revaluation of cash advances to Helomics of $1.2 million and a gain of $6.2 million on a revaluation of equity method investment.
Outlook
Management continues to focus its resources on the Helomics and TumorGenesis divisions and the Company’s primary mission of applying artificial intelligence to precision medicine, drug discovery and the mediums used to replace rats and mice in preliminary cancer studies. Management reaffirms that it is focusing the majority of its resources on maximizing opportunities within the Company’s precision medicine business.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com. Forward-Looking Statements
Portions of the narrative set for this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.
These factors include, in addition to those mentioned elsewhere herein:
Investor Relations Contact:
Hayden IR — Tables Follow – PREDICTIVE ONCOLOGY INC. PREDICTIVE ONCOLOGY INC.
James Carbonara
(646)-755-7412
[email protected]
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2020
December 31, 2019
(unaudited)
(audited)
ASSETS
Current Assets:
Cash and Cash Equivalents
$
3,394,078
$
150,831
Accounts Receivable
272,493
297,055
Inventories
235,368
190,156
Prepaid Expense and Other Assets
426,704
160,222
Total Current Assets
4,328,643
798,264
Fixed Assets, net
2,409,721
1,507,799
Intangibles, net
3,539,597
3,649,412
Lease Right-of-Use Assets
1,528,150
729,745
Goodwill
15,690,290
15,690,290
Total Assets
$
27,496,401
22,375,510
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable
$
2,449,046
$
3,155,641
Notes Payable – Net of Discounts of $282,099 and $350,426
4,412,377
4,795,800
Accrued Expenses
2,649,160
2,371,633
Derivative Liability
4,629,570
50,989
Deferred Revenue
38,582
40,384
Lease Liability
473,043
459,481
Total Current Liabilities
14,651,778
10,873,928
Lease Liability – Net of current portion
1,055,107
270,264
Other long-term liabilities
98,358
–
Total Liabilities
15,805,243
11,144,192
Stockholders’ Equity:
Preferred Stock, 20,000,000 authorized inclusive of designated below
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 and 79,246 shares outstanding
792
792
Series D Convertible Preferred Stock, $.01 par value, 3,500,000 shares authorized, 0 and 3,500,000 outstanding
–
35,000
Series E Convertible Preferred Stock, $.01 par value, 350 shares authorized, 0 and 258 outstanding
–
3
Common Stock, $.01 par value, 100,000,000 shares authorized, 13,190,787 and 4,056,652 outstanding
131,908
40,567
Additional paid-in capital
102,163,864
93,653,667
Accumulated Deficit
(90,605,406
)
(82,498,711
)
Total Stockholders’ Equity
11,691,158
11,231,318
Total Liabilities and Stockholders’ Equity
$
27,496,401
$
22,375,510
CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS
(Unaudited)
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Revenue
$
182,784
$
286,151
$
477,727
$
541,392
Cost of goods sold
85,261
118,390
177,918
192,106
Gross margin
97,523
167,761
299,809
349,286
General and administrative expense
3,211,817
3,310,368
6,040,293
4,808,314
Operations expense
521,116
1,271,258
1,069,869
1,737,824
Sales and marketing expense
133,015
685,029
397,424
1,239,245
Total operating loss
(3,768,425
)
(5,098,894
)
(7,207,777
)
(7,436,097
)
Gain on revaluation of cash advances to Helomics
–
1,222,244
–
1,222,244
Other income
52,965
(3,223
)
52,968
50,209
Other expense
(729,837
)
(607,343
)
(1,846,912
)
(1,157,711
)
Gain (loss) on derivative instruments
(422,081
)
(211,940
)
(394,974
)
(231,348
)
Gain on notes receivables associated with asset purchase
1,290,000
–
1,290,000
–
Loss on equity method investment
–
–
–
439,637
Gain on revaluation of equity method in investment
–
6,164,260
–
6,164,260
Net income (loss)
$
(3,577,378
)
$
1,465,104
$
(8,106,695
)
$
(1,828,080
)
Deemed dividend on Series E Convertible Preferred Stock
–
20,398
–
20,398
Net income (loss) attributable to common shareholders per common shares-basic and diluted
$
(3,577,378
)
$
1,444,706
$
(8,106,695
)
$
(1,848,478
)
Gain (loss) per common share basic
$
(0.36
)
$
0.49
$
(1.10
)
$
(0.81
)
Gain (loss) per common share diluted
(0.36
)
0.24
(1.10
)
(0.81
)
Weighted average shared used in computation – basic
9,838,152
2,960,937
7,362,240
2,274,754
Weighted average shared used in computation – diluted
9,838,152
6,007,078
7,362,240
2,274,754
Artificial Intelligence
Delvitech and Eurotech: a partnership to take quality control to the next level
![delvitech-and-eurotech:-a-partnership-to-take-quality-control-to-the-next-level](https://roboticulized.com/wp-content/uploads/2024/07/151031-delvitech-and-eurotech-a-partnership-to-take-quality-control-to-the-next-level.jpg)
From Mathematical Models to AI-driven Automated Optical Inspection
AMARO, Italy, July 4, 2024 /PRNewswire/ — Delvitech, a leader in 3D automated optical inspection for assembled printed circuit boards leveraging artificial intelligence, has joined forces with Eurotech, a global innovator in ultra-high-performance Edge AI Computers, to revolutionize quality control technology.
Delvitech’s patented integrated optical inspection technology, designed to collect comprehensive data to drive neural networks in optical inspection, gains crucial support from Eurotech’s hardware. This collaboration boosts the efficiency of assembling printed circuit boards, greatly increasing assembly machine uptime and significantly reducing waste and rework.
Employing the patented optical head, Delvitech captures detailed images that are processed through its software, adept at detecting assembly and welding errors in the electronics manufacturing process. Eurotech’s hardware complements this system by offering the speed and computational accuracy necessary to handle the massive influx of data required for the algorithms to produce desired outcomes.
This integrated 3D solution is highly competitive and flexible, allowing customization to meet specific customer needs. As board electronics become increasingly complex, Delvitech’s technology surpasses traditional mathematical models by analyzing a variety of components, such as metal parts, transparent glues, and silicone elements.
Moreover, this collaboration enables Delvitech and Eurotech to offer a solution that not only identifies errors but also drives AI models to detect deviations and trends, proactively preventing future errors and enhancing process quality.
“In an environment where quality control demands are continuously growing, it is crucial to develop optical inspection systems with optimal performance and partner with providers of state-of-the-art solutions. Eurotech offers highly reliable solutions, extensively tested to meet our high-performance requirements,” said Roberto Gatti, CEO of Delvitech.
Paul Chawla, CEO of Eurotech, added, “Our collaboration with Delvitech showcases the power of our Edge AI solutions. We empower our partners to deliver efficient, cost-effective, and scalable solutions where accuracy and speed are critical.”
Currently focusing on optical control of boards and soon semiconductors, the partnership aspires to expand into other sectors, including medical and food, with a strong emphasis on cybersecurity and sustainability.
As Delvitech and Eurotech continue to innovate, they bring unique strengths to the table. Delvitech commits to “less errors, less waste, less CO2, more future,” while Eurotech focuses on “more security, more resilience, more efficiency,” ensuring effective asset management and rapid scalability. These commitments reflect common shared goals of exceeding market and customer expectations today and in the future.
About Eurotech
Eurotech (ETH.IM) is a multinational company that designs, develops, and supplies Edge Computers and Internet of Things (IoT) solutions – complete with services, software and hardware – to system integrators and enterprises. By adopting Eurotech solutions, customers have access to IoT building blocks and software platforms, to Edge Gateways to enable asset monitoring, and to High Performance Edge Computers (HPEC) created for Artificial Intelligence (AI) applications. To offer increasingly comprehensive solutions,
Eurotech has partnered with leading companies in their field of action, with the view of creating “best in class” solutions for the Industrial Internet of Things.
Learn more
Contacts
Corporate Communication Federica Maion Tel. +39 0433 485411 [email protected]
About Delvitech
Delvitech is a Swiss based leading provider of AI-based automatic optical inspection (AOI) solutions aimed at revolutionizing the printed circuit board (PCB) assembly and electronics manufacturing landscape. With a focus on innovation and quality, Delvitech is capable of elevating both cost and process efficiencies, ensuring scalability and inspection repeatability on all production lines. It aspires to make the PCB production process swifter, more reliable, and highly scalable by not only detecting errors, but inspecting the whole production process. Delvitech solution is not just about minimizing errors; it is a commitment to reducing waste, cutting down CO2 emissions, and pioneering the path as the first sustainable AOI solution.
Contacts
Marketing DepartmentFederica RiosaTel. +41 916 460 [email protected]
Logo – https://mma.prnewswire.com/media/1897403/Eurotech_Logo.jpgLogo – https://mma.prnewswire.com/media/2453717/Delvitech_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/delvitech-and-eurotech-a-partnership-to-take-quality-control-to-the-next-level-302189001.html
Artificial Intelligence
Converge Technology Solutions Announces Deconsolidation of Portage CyberTech Inc.
![converge-technology-solutions-announces-deconsolidation-of-portage-cybertech-inc.](https://roboticulized.com/wp-content/uploads/2024/07/151017-converge-technology-solutions-announces-deconsolidation-of-portage-cybertech-inc.png)
TORONTO and GATINEAU, QC, July 3, 2024 /PRNewswire/ — Converge Technology Solutions Corp. (“Converge” or the “Company”) (TSX: CTS) (FSE: 0ZB) (OTCQX: CTSDF) today announced that, as of June 27, 2024, the Company has fulfilled the criteria necessary for the deconsolidation of its majority owned subsidiary, Portage CyberTech Inc. (“Portage CyberTech”) for accounting purposes, following Converge’s decision to relinquish its right to majority representation on the board of directors of Portage CyberTech (the “Portage Board”) pursuant to a voting agreement dated as of June 27, 2024 (“Voting Agreement”).
In conjunction with the execution of the Voting Agreement, Portage CyberTech announced it has entered into a new stand-alone credit facility with the Canadian Imperial Bank of Commerce (“CIBC”), for up to $15 million, of which $10 million will be drawn immediately and the additional $5 million is contingent on achieving future financial targets.
“Successfully meeting the criteria necessary to deconsolidate Portage CyberTech from Converge is an important step for each company,” stated Shaun Maine, Group CEO of Converge. “This pivot will allow Converge to remain a strong partner and advocate for Portage CyberTech’s industry leading products and positions Portage CyberTech on its own accelerated growth path, operating completely independent of Converge.”
Converge Group CEO, Shaun Maine will maintain the position as Chairman of the Portage Board, which consists of three members. Converge currently retains ownership of approximately 51% of the outstanding common shares of Portage CyberTech in addition to the $25 million long-term loan entered into with Portage CyberTech.
About Portage CyberTech, A Converge Company
Portage CyberTech powers trusted digital transactions between individuals, businesses, and government organizations. Driven by some of the most ambitious digital projects and our desire to raise the visibility of our clients at home and abroad, our committed team of experts in all things digital – identity, access management, trusted services, and communications, have created the solutions designed to reach your customers. For more information, visit portagecybertech.com.
About Converge
Converge Technology Solutions Corp. is a services-led, software-enabled, IT & Cloud Solutions provider focused on delivering industry-leading solutions. Converge’s global approach delivers advanced analytics, artificial intelligence (AI), application modernization, cloud platforms, cybersecurity, digital infrastructure, and digital workplace offerings to clients across various industries. The Company supports these solutions with advisory, implementation, and managed services expertise across all major IT vendors in the marketplace. This multi-faceted approach enables Converge to address the unique business and technology requirements for all clients in the public and private sectors. For more information, visit convergetp.com.
Forward-Looking Information
This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation regarding Converge, Portage Cybertech and their businesses. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected” “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”. “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.
Although the Company bases these forward-looking statements on assumptions that it believes are reasonable when made, the Company cautions investors that forward-looking statements are not guarantees of future performance and that its or Portage Cybertech’s actual results of operations, financial condition and position in the industry in which they each operate may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if the Company or Portage Cybertech’s results of operations, financial condition and position in the industry in which they each operate are consistent with the forward-looking statements contained in this press release, those results of developments may not be indicative of results or developments in subsequent periods.
There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents the Company’s expectations as of the date specified herein, and are subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information or to publicly announce the results of any revisions to any of those statements, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.
For further information contact: Converge Technology Solutions Corp., Email: [email protected], Phone: 416-360-1495
View original content:https://www.prnewswire.co.uk/news-releases/converge-technology-solutions-announces-deconsolidation-of-portage-cybertech-inc-302189238.html
Artificial Intelligence
Trianz Welcomes Priyanshu Singh as Vice President & Chief of Staff to the CEO
![trianz-welcomes-priyanshu-singh-as-vice-president-&-chief-of-staff-to-the-ceo](https://roboticulized.com/wp-content/uploads/2024/07/151015-trianz-welcomes-priyanshu-singh-as-vice-president-chief-of-staff-to-the-ceo.jpg)
SANTA CLARA, Calif., July 3, 2024 /PRNewswire/ — Trianz, a global digital transformation technology solutions and services firm, is thrilled to announce the appointment of Priyanshu Singh as its new VP & Chief of Staff. This strategic hire comes at a pivotal moment as Trianz continues to experience remarkable growth, driven by its shift to an ‘IP-led digital transformation’ model with hyper-automated platforms like Concierto – the hybrid cloud migrations and operations platform, and Extrica – the data to AI platform, accelerating customer success.
As Chief of Staff, Priyanshu Singh will play a crucial role in leading Trianz’ IP-led strategy development, operational excellence, and key execution teams, supporting the CEO’s office. He will design and implement organization-wide processes and capabilities and create and oversee opearational monitoring models and enterprise analytics. His expertise in business and competitive strategy, customer experience, digital transformation, and operations across multiple industries will be a tremendous asset as Trainz prepares to scale in this new model.
A graduate of the prestigious National Defense Academy, Priyanshu began his career in the Indian Army. After completing his MBA from IIM Calcutta, Priyanshu joined McKinsey & Company, working on strategy and business model design for clients across industries. His distinguished career includes key leadership roles at Uber, Lithium Urban Technologies, The Adecco Group, and Honeywell. Known for his excellence in reimagining offerings, exceeding support targets, and spearheading innovative solutions, Priyanshu has consistently delivered exceptional results. In 2016, he was recognized as one of India’s ‘Top 40 Under 40′ business leaders by The Economic Times and Spencer Stuart.
“We are excited to welcome Priyanshu Singh to our leadership team. With his military background, he brings a unique blend of discipline and strategic insight to Trianz,” said Sri Manchala, CEO of Trianz. “His deep expertise and forward-thinking approach will be invaluable in shaping our vision as we continue to leverage the power of our in-house innovations, AI, and cutting-edge tools. With Priyanshu on board, I am confident we will accelerate our transformations and achieve operational excellence.”
“I am honored to join Trianz as the new Chief of Staff,” said Priyanshu. “In this role, I will focus on bridging the gap between strategy and execution, ensuring our teams are aligned to achieve our committed objectives. I am passionate about problem-solving and look forward to collaborating with leaders across the organization to foster a culture of agility, adaptability, and continuous improvement. I am thrilled to be part of this dynamic team and confident we can achieve great things together.”
Priyanshu’s appointment underscores Trianz’ commitment to strengthening its leadership team and ensuring the company is well-prepared to seize future opportunities.
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our “IP Led Transformations” approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto , Extrica , and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media Team [email protected]+1-408-387-5800
Logo: https://mma.prnewswire.com/media/2441367/Trianz_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-priyanshu-singh-as-vice-president–chief-of-staff-to-the-ceo-302188852.html
-
Artificial Intelligence6 days ago
Spotlight on Authentic AI: Developers Making Real Contributions Beyond AI Washing Claims
-
Artificial Intelligence6 days ago
Asia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
-
Artificial Intelligence6 days ago
CO2 AI Launches First Solution to Compute Product Emissions at Scale
-
Artificial Intelligence5 days ago
Lucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024
-
Artificial Intelligence6 days ago
Tech Companies Leading the Charge in the Transformative AI Era
-
Uncategorized7 days ago
Internal audit’s role in the new European Union’s Artificial Intelligence Act
-
Artificial Intelligence6 days ago
North American grocery retailer digitizes stores with Pricer Plaza in 90 MSEK order
-
Artificial Intelligence6 days ago
Hybrid Memory Cube Market Size to Grow USD 18651.2 Million by 2030 at a CAGR of 18.6% | Valuates Reports